Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies
Abstract Fast, accurate and reliable methods to quantify the amount of myelin still lack, both in humans and experimental models. The overall objective of the present study was to demonstrate that sphingomyelin (SM) in the cerebrospinal fluid (CSF) of patients affected by demyelinating neuropathies...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9565e9d63f784317a3a29b6d115273b5 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:9565e9d63f784317a3a29b6d115273b5 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:9565e9d63f784317a3a29b6d115273b52021-12-02T16:07:44ZSphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies10.1038/s41598-017-08314-12045-2322https://doaj.org/article/9565e9d63f784317a3a29b6d115273b52017-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-08314-1https://doaj.org/toc/2045-2322Abstract Fast, accurate and reliable methods to quantify the amount of myelin still lack, both in humans and experimental models. The overall objective of the present study was to demonstrate that sphingomyelin (SM) in the cerebrospinal fluid (CSF) of patients affected by demyelinating neuropathies is a myelin biomarker. We found that SM levels mirror both peripheral myelination during development and small myelin rearrangements in experimental models. As in acquired demyelinating peripheral neuropathies myelin breakdown occurs, SM amount in the CSF of these patients might detect the myelin loss. Indeed, quantification of SM in 262 neurological patients showed a significant increase in patients with peripheral demyelination (p = 3.81 * 10 − 8) compared to subjects affected by non-demyelinating disorders. Interestingly, SM alone was able to distinguish demyelinating from axonal neuropathies and differs from the principal CSF indexes, confirming the novelty of this potential CSF index. In conclusion, SM is a specific and sensitive biomarker to monitor myelin pathology in the CSF of peripheral neuropathies. Most importantly, SM assay is simple, fast, inexpensive, and promising to be used in clinical practice and drug development.Giovanna CapodiventoDavide VisigalliMartina GarneroRoberto FancelluMichela Demetra FerraraAbdul BasitZeeshan HamidVito Paolo PastoreSilvano GaribaldiAndrea ArmirottiGianluigi MancardiCarlo SerratiElisabetta CapelloAngelo SchenoneLucilla NobbioNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-9 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Giovanna Capodivento Davide Visigalli Martina Garnero Roberto Fancellu Michela Demetra Ferrara Abdul Basit Zeeshan Hamid Vito Paolo Pastore Silvano Garibaldi Andrea Armirotti Gianluigi Mancardi Carlo Serrati Elisabetta Capello Angelo Schenone Lucilla Nobbio Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies |
| description |
Abstract Fast, accurate and reliable methods to quantify the amount of myelin still lack, both in humans and experimental models. The overall objective of the present study was to demonstrate that sphingomyelin (SM) in the cerebrospinal fluid (CSF) of patients affected by demyelinating neuropathies is a myelin biomarker. We found that SM levels mirror both peripheral myelination during development and small myelin rearrangements in experimental models. As in acquired demyelinating peripheral neuropathies myelin breakdown occurs, SM amount in the CSF of these patients might detect the myelin loss. Indeed, quantification of SM in 262 neurological patients showed a significant increase in patients with peripheral demyelination (p = 3.81 * 10 − 8) compared to subjects affected by non-demyelinating disorders. Interestingly, SM alone was able to distinguish demyelinating from axonal neuropathies and differs from the principal CSF indexes, confirming the novelty of this potential CSF index. In conclusion, SM is a specific and sensitive biomarker to monitor myelin pathology in the CSF of peripheral neuropathies. Most importantly, SM assay is simple, fast, inexpensive, and promising to be used in clinical practice and drug development. |
| format |
article |
| author |
Giovanna Capodivento Davide Visigalli Martina Garnero Roberto Fancellu Michela Demetra Ferrara Abdul Basit Zeeshan Hamid Vito Paolo Pastore Silvano Garibaldi Andrea Armirotti Gianluigi Mancardi Carlo Serrati Elisabetta Capello Angelo Schenone Lucilla Nobbio |
| author_facet |
Giovanna Capodivento Davide Visigalli Martina Garnero Roberto Fancellu Michela Demetra Ferrara Abdul Basit Zeeshan Hamid Vito Paolo Pastore Silvano Garibaldi Andrea Armirotti Gianluigi Mancardi Carlo Serrati Elisabetta Capello Angelo Schenone Lucilla Nobbio |
| author_sort |
Giovanna Capodivento |
| title |
Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies |
| title_short |
Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies |
| title_full |
Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies |
| title_fullStr |
Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies |
| title_full_unstemmed |
Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies |
| title_sort |
sphingomyelin as a myelin biomarker in csf of acquired demyelinating neuropathies |
| publisher |
Nature Portfolio |
| publishDate |
2017 |
| url |
https://doaj.org/article/9565e9d63f784317a3a29b6d115273b5 |
| work_keys_str_mv |
AT giovannacapodivento sphingomyelinasamyelinbiomarkerincsfofacquireddemyelinatingneuropathies AT davidevisigalli sphingomyelinasamyelinbiomarkerincsfofacquireddemyelinatingneuropathies AT martinagarnero sphingomyelinasamyelinbiomarkerincsfofacquireddemyelinatingneuropathies AT robertofancellu sphingomyelinasamyelinbiomarkerincsfofacquireddemyelinatingneuropathies AT michelademetraferrara sphingomyelinasamyelinbiomarkerincsfofacquireddemyelinatingneuropathies AT abdulbasit sphingomyelinasamyelinbiomarkerincsfofacquireddemyelinatingneuropathies AT zeeshanhamid sphingomyelinasamyelinbiomarkerincsfofacquireddemyelinatingneuropathies AT vitopaolopastore sphingomyelinasamyelinbiomarkerincsfofacquireddemyelinatingneuropathies AT silvanogaribaldi sphingomyelinasamyelinbiomarkerincsfofacquireddemyelinatingneuropathies AT andreaarmirotti sphingomyelinasamyelinbiomarkerincsfofacquireddemyelinatingneuropathies AT gianluigimancardi sphingomyelinasamyelinbiomarkerincsfofacquireddemyelinatingneuropathies AT carloserrati sphingomyelinasamyelinbiomarkerincsfofacquireddemyelinatingneuropathies AT elisabettacapello sphingomyelinasamyelinbiomarkerincsfofacquireddemyelinatingneuropathies AT angeloschenone sphingomyelinasamyelinbiomarkerincsfofacquireddemyelinatingneuropathies AT lucillanobbio sphingomyelinasamyelinbiomarkerincsfofacquireddemyelinatingneuropathies |
| _version_ |
1718384732549414912 |